Psoriatic Arthritis

Latest News

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

TNFi persistence and factors influencing persistence were investigated in patients who were treated with TNFi therapy for the first time.

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

Administration of abatacept may improve patient-reported outcomes in individuals with active psoriatic arthritis and elevated levels of C-reactive protein, irrespective of tumor necrosis factor inhibitor treatment history.

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

The guideline includes recommendations for treating adult patients with active psoriatic arthritis.

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

The risk for symptom flares is substantial after TNFi discontinuation in patients with psoriatic arthritis who had achieved remission/low disease activity.

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

With the exception of sedentary lifestyle, cardiovascular risk factors were not found to impact the likelihood of achieving minimal disease activity among patients with psoriatic arthritis.

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.

Secukinumab Effectively Inhibits Radiographic Progression of PsA

Secukinumab Effectively Inhibits Radiographic Progression of PsA

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Sign Up for Free e-newsletters